Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioNTech SE stock logo
BNTX
BioNTech
$104.15
+0.1%
$101.14
$76.53
$131.49
$24.99B1.07909,960 shs872,391 shs
GSK plc stock logo
GSK
GSK
$39.83
+2.2%
$37.57
$31.72
$45.93
$82.18B0.564.75 million shs8.03 million shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$156.32
+0.3%
$159.36
$140.68
$169.99
$376.12B0.497.92 million shs9.59 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$28.54
+2.6%
$29.91
$23.15
$170.47
$11.03B2.237.39 million shs7.71 million shs
Novavax, Inc. stock logo
NVAX
Novavax
$6.67
+3.9%
$7.07
$4.29
$23.86
$1.07B3.158.37 million shs5.23 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$24.41
+2.6%
$24.48
$20.92
$31.54
$138.44B0.6740.88 million shs53.88 million shs
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$62.40
+2.5%
$75.46
$48.01
$173.25
$6.05B0.931.43 million shs1.58 million shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioNTech SE stock logo
BNTX
BioNTech
0.00%-0.65%+9.53%-14.16%+18.25%
GSK plc stock logo
GSK
GSK
+2.73%+6.91%+1.00%+11.60%-6.01%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
+0.35%-1.13%-4.72%+3.06%+6.17%
Moderna, Inc. stock logo
MRNA
Moderna
+1.31%+8.08%-10.60%-31.68%-75.08%
Novavax, Inc. stock logo
NVAX
Novavax
-4.18%+2.72%-8.29%-27.13%+49.65%
Pfizer Inc. stock logo
PFE
Pfizer
+3.30%+5.59%-5.56%-10.68%-7.21%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
-1.07%+2.60%-13.58%-47.29%-52.76%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BioNTech SE stock logo
BNTX
BioNTech
2.3725 of 5 stars
4.42.00.00.02.20.80.0
GSK plc stock logo
GSK
GSK
1.2757 of 5 stars
1.33.02.50.02.00.01.3
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
4.2943 of 5 stars
2.33.04.23.92.72.50.6
Moderna, Inc. stock logo
MRNA
Moderna
4.3324 of 5 stars
4.01.00.04.63.32.50.6
Novavax, Inc. stock logo
NVAX
Novavax
3.6226 of 5 stars
3.21.00.04.73.10.80.6
Pfizer Inc. stock logo
PFE
Pfizer
4.9766 of 5 stars
3.33.04.24.33.13.33.1
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
4.7324 of 5 stars
4.42.00.04.22.72.51.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioNTech SE stock logo
BNTX
BioNTech
2.89
Moderate Buy$143.4437.72% Upside
GSK plc stock logo
GSK
GSK
2.55
Moderate Buy$40.581.89% Upside
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.63
Moderate Buy$171.829.92% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.04
Hold$58.70105.68% Upside
Novavax, Inc. stock logo
NVAX
Novavax
2.43
Hold$18.00169.87% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.53
Moderate Buy$29.6421.44% Upside
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
2.83
Moderate Buy$158.70154.32% Upside

Current Analyst Ratings Breakdown

Latest PFE, BNTX, MRNA, JNJ, NVAX, SRPT, and GSK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/30/2025
Pfizer Inc. stock logo
PFE
Pfizer
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$24.00 ➝ $25.00
4/24/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/22/2025
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight ➝ Neutral$24.00
4/21/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$182.00 ➝ $110.00
4/17/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$166.00 ➝ $165.00
4/17/2025
Moderna, Inc. stock logo
MRNA
Moderna
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
4/16/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform ➝ Market Perform
4/16/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$181.00 ➝ $181.00
4/16/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$164.00 ➝ $169.00
4/16/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$75.00 ➝ $75.00
4/15/2025
GSK plc stock logo
GSK
GSK
BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$35.25
(Data available from 4/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioNTech SE stock logo
BNTX
BioNTech
$2.75B9.08$4.48 per share23.25$92.17 per share1.13
GSK plc stock logo
GSK
GSK
$31.38B2.62$6.30 per share6.32$8.07 per share4.94
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$89.33B4.21$12.84 per share12.17$29.69 per share5.27
Moderna, Inc. stock logo
MRNA
Moderna
$3.20B3.45N/AN/A$28.33 per share1.01
Novavax, Inc. stock logo
NVAX
Novavax
$682.16M1.57N/AN/A($6.04) per share-1.10
Pfizer Inc. stock logo
PFE
Pfizer
$63.63B2.18$3.83 per share6.38$15.81 per share1.54
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$1.90B3.18N/AN/A$9.19 per share6.79
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioNTech SE stock logo
BNTX
BioNTech
$1.01B-$3.00N/AN/AN/A-15.16%-2.35%-2.05%5/5/2025 (Estimated)
GSK plc stock logo
GSK
GSK
$3.29B$1.5925.058.571.128.13%48.59%11.11%4/30/2025 (Estimated)
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$14.07B$8.9923.5114.122.5618.20%34.24%13.63%7/16/2025 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$9.28N/AN/AN/A-110.04%-28.74%-21.83%5/1/2025 (Estimated)
Novavax, Inc. stock logo
NVAX
Novavax
-$545.06M-$1.33N/A83.382.85-32.18%N/A-17.05%5/9/2025 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$8.03B$1.4117.318.060.6412.62%19.47%8.09%N/A
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
-$535.98M$2.2849.925.70N/A7.43%11.00%3.35%5/6/2025 (Estimated)

Latest PFE, BNTX, MRNA, JNJ, NVAX, SRPT, and GSK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2025Q1 2025
Novavax, Inc. stock logo
NVAX
Novavax
$0.19N/AN/AN/A$204.08 millionN/A
5/6/2025Q1 2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$2.20N/AN/AN/A$685.75 millionN/A
5/5/2025Q1 2025
BioNTech SE stock logo
BNTX
BioNTech
-$2.68N/AN/AN/A$175.90 millionN/A
5/1/2025Q1 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.90N/AN/AN/A$130.35 millionN/A
4/30/2025Q1 2025
GSK plc stock logo
GSK
GSK
$1.08$1.13+$0.05$1.00$7.52 billion$10.06 billion
4/29/2025Q1 2025
Pfizer Inc. stock logo
PFE
Pfizer
$0.67$0.92+$0.25$0.52$14.43 billion$13.72 billion
4/15/2025Q1 2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.59$2.77+$0.18$4.54$21.65 billion$21.89 billion
3/10/2025Q4 2024
BioNTech SE stock logo
BNTX
BioNTech
$0.38$1.08+$0.70$1.15$1.24 billion$1.19 billion
2/27/2025Q4 2024
Novavax, Inc. stock logo
NVAX
Novavax
-$0.75-$0.51+$0.24-$0.51$85.48 million$88.31 million
2/5/2025Q4 2024
GSK plc stock logo
GSK
GSK
$0.44$0.59+$0.15$0.26$7.75 billionN/A
2/4/2025Q4 2024
Pfizer Inc. stock logo
PFE
Pfizer
$0.48$0.63+$0.15$0.07$17.26 billion$17.76 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioNTech SE stock logo
BNTX
BioNTech
$1.531.47%N/AN/A N/A
GSK plc stock logo
GSK
GSK
$1.604.02%-17.33%100.63%N/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$5.203.33%+5.43%57.84%64 Years
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Novavax, Inc. stock logo
NVAX
Novavax
N/AN/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.727.05%+2.50%121.99%16 Years
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
N/AN/AN/AN/AN/A

Latest PFE, BNTX, MRNA, JNJ, NVAX, SRPT, and GSK Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/23/2025
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.437.69%5/9/20255/9/20256/13/2025
4/15/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
quarterly$1.303.37%5/27/20255/27/20256/10/2025
2/5/2025
GSK plc stock logo
GSK
GSK
quarterly$0.39324.2%2/21/20252/21/20254/10/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioNTech SE stock logo
BNTX
BioNTech
0.01
7.33
7.21
GSK plc stock logo
GSK
GSK
1.12
0.78
0.52
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.43
1.11
0.86
Moderna, Inc. stock logo
MRNA
Moderna
N/A
3.67
3.62
Novavax, Inc. stock logo
NVAX
Novavax
N/A
0.93
0.93
Pfizer Inc. stock logo
PFE
Pfizer
0.63
1.00
0.73
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
0.93
3.84
3.03

Institutional Ownership

CompanyInstitutional Ownership
BioNTech SE stock logo
BNTX
BioNTech
15.52%
GSK plc stock logo
GSK
GSK
15.74%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
69.55%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Novavax, Inc. stock logo
NVAX
Novavax
53.04%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
86.68%

Insider Ownership

CompanyInsider Ownership
BioNTech SE stock logo
BNTX
BioNTech
19.20%
GSK plc stock logo
GSK
GSK
10.00%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.16%
Moderna, Inc. stock logo
MRNA
Moderna
11.00%
Novavax, Inc. stock logo
NVAX
Novavax
1.00%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
7.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioNTech SE stock logo
BNTX
BioNTech
3,080239.97 million193.71 millionOptionable
GSK plc stock logo
GSK
GSK
90,1002.06 billion1.87 billionOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
152,7002.41 billion2.40 billionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
3,900386.62 million324.40 millionOptionable
Novavax, Inc. stock logo
NVAX
Novavax
1,990160.84 million158.58 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
83,0005.67 billion5.66 billionOptionable
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
84097.03 million88.17 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
BioNTech stock logo

BioNTech NASDAQ:BNTX

$104.15 +0.15 (+0.14%)
As of 04:00 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

GSK stock logo

GSK NYSE:GSK

$39.83 +0.86 (+2.21%)
As of 03:59 PM Eastern

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Johnson & Johnson stock logo

Johnson & Johnson NYSE:JNJ

$156.32 +0.41 (+0.26%)
As of 03:59 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Moderna stock logo

Moderna NASDAQ:MRNA

$28.54 +0.72 (+2.59%)
As of 04:00 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Novavax stock logo

Novavax NASDAQ:NVAX

$6.67 +0.25 (+3.89%)
As of 04:00 PM Eastern

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Pfizer stock logo

Pfizer NYSE:PFE

$24.41 +0.62 (+2.61%)
As of 03:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Sarepta Therapeutics stock logo

Sarepta Therapeutics NASDAQ:SRPT

$62.40 +1.55 (+2.55%)
As of 04:00 PM Eastern

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.